Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Curiox Biosystems Names Shanin Barican VP of Business Development

By Public Technologies
  • Curiox Biosystems appointed Shanin Barican vice president of business development and Kristine Friscino vice president of marketing.
  • Barican previously served as senior director of business development at Opentrons Labworks.
  • Friscino most recently served as vice president of marketing and product at Nuclera.
  • Elizabeth Woo, formerly Thermo Fisher Scientific’s vice president of cell, gene and advanced therapies, joined the newly formed Strategic Advisory Board.
  • David Newble, who previously led TAP Biosystems and SPT Labtech, also joined the advisory board to guide adoption and commercial expansion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curiox Biosystems Co., Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610291000BIZWIRE_USPR_____20261029_BW482791) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.